首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor
【24h】

Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor

机译:GCN5组蛋白乙酰转移酶与双底物抑制剂结合的结构

获取原文
获取原文并翻译 | 示例
       

摘要

Histone acetyltransferases (HATs) use acetyl CoA to acetylate target lysine residues within histones and other transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequence and substrate preference. Several HAT proteins have been implicated in human cancer. We have previously reported on the preparation of peptide-CoA conjugate inhibitors with distinct specificities for the p300/CBP [cAMP response element binding protein (CREB)-binding protein] or GCN5 HAT subfamilies. Here we report on the crystal structure of the GCN5 HAT bound to a peptide-CoA conjugate containing CoA co-valently attached through an isopropionyl linker to Lys-14 of a 20-aa N-terminal fragment of histone H3. Surprisingly, the structure reveals that the H3 portion of the inhibitor is bound outside of the binding site for the histone substrate and that only five of the 20 aa residues of the inhibitor are ordered. Rearrangements within the C-terminal region of the GCN5 protein appear to mediate this peptide displacement. Mutational and enzymatic data support the hypothesis that the observed structure corresponds to a late catalytic intermediate. The structure also provides a structural scaffold for the design of HAT-specific inhibitors that may have therapeutic applications for the treatment of HAT-mediated cancers.
机译:组蛋白乙酰转移酶(HATs)使用乙酰辅酶A乙酰化组蛋白和其他转录因子(例如p53肿瘤抑制因子)中的靶赖氨酸残基,以促进基因激活。 HAT酶属于亚家族,其序列和底物偏好存在差异。几种HAT蛋白已与人类癌症有关。我们以前曾报道过对p300 / CBP [cAMP反应元件结合蛋白(CREB)结合蛋白]或GCN5 HAT亚家族具有不同特异性的肽-CoA共轭抑制剂的制备。在这里,我们报告的GCN5 HAT的晶体结构与肽-CoA缀合物结合,该缀合物包含通过异丙酰基接头与组蛋白H3的20-aa N端片段的Lys-14共价连接的CoA。令人惊讶地,该结构揭示了抑制剂的H3部分结合在组蛋白底物的结合位点之外,并且抑制剂的20个氨基酸残基中只有五个是有序的。 GCN5蛋白的C端区域内的重排似乎介导了这种肽置换。突变和酶促数据支持以下假设:观察到的结构对应于后期催化中间体。该结构还提供了用于设计HAT特异性抑制剂的结构支架,该抑制剂可能具有治疗HAT介导的癌症的治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号